ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June.
A medical doctor surrounded by advanced technology in the operating room.
ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings.
This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue.
Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation.
ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments.
Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables.
ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Oliveda International, Inc. (OLVI) Subsidiary Olive Tree People Canada Inc. Brings Its Waterless Beauty to Canada in July 2025
SANTA MONICA, CA, June 30, 2025 (GLOBE NEWSWIRE) — Oliveda International, Inc. (OTC Pink: OLVI) today announced that after a true waterless beauty movement emerged in the United States within just two years, with over 60,000 waterless beauty consultants, and Olive Tree People USA Inc. exploded from 40 to over 10,000 packages per day and up to 4 million in sales per day in 2024 alone, olive farmer and CEO Thomas Lommel has set the course for global expansion by establishing subsidiaries in Canada and Europe. Olive Tree People Canada Inc., based in Edmonton, Alberta, will begin its pre-launch phase in Canada in July 2025, and in October 2025, Olive Tree People Europe AG, based in Switzerland, will drive expansion in Europe. As the Los Angeles Times reported in May 2025, Olive Tree People Inc. is the fastest-growing waterless beauty company in the U.S. With sales of $105 million in its second year, Olive Tree People is growing 600% faster than Beautycounter in its second year and also grew faster than many established celebrity brands such as JLO Beauty and many others. When asked about the secret to its success, olive farmer and CEO Thomas Lommel replied, 'It took me over 21 years to realize that direct-to-consumer sales, rather than retail, is the perfect match for waterless beauty. No marketing campaign in the world – not even the largest campaign and not the most exclusive retail stores – can communicate and deliver waterless beauty more successfully than our waterless beauty consultants in the U.S., and soon in Canada and Europe.' When asked why, Mr. Lommel replied, 'It's simple: They breathe waterless beauty 24/7. Our waterless beauty consultants don't sell; they educate. In so-called Waterless Glow workshops, interested customers learn all about waterless beauty and how it differs from conventional cosmetics. Most of them decide to try us when they hear we offer a 365-day satisfaction guarantee. Many of them come back and buy more products. We've been educating women and men in retail for 21 years, and I can tell you, that's not possible in retail. The women and men on the shelves in retail stores do an excellent job, but they are responsible for dozens of brands and therefore, can't do what our Waterless Beauty consultants 24/7. That's why, after more than 20 years, we are also pursuing a direct-to-consumer approach in Europe with the goal of informing and educating the 448 million women in Europe. We couldn't be prouder of our Waterless Beauty Consultants and therefore, regularly celebrate them in magazines like the Time issue 'Women of the Year,' Vogue USA, or in June 2025, in Vanity Fair , and many others.' Mr. Lommel explained why Waterless Beauty, with over $22 billion, is the fastest-growing segment of the entire beauty industry, 'People understand that Waterless Beauty is the next, and most importantly, true, clean beauty, and they understand that what they wouldn't drink/eat (water with preservatives and refined oils, or even worse, petroleum) shouldn't be applied to their skin either.' When asked about the fact that Olive Tree People is currently valued at over $1 billion, as reported by the LA Times , Mr. Lommel replied, 'I believe that the value of a tree cannot be measured in dollars, and we have saved more than 31,000 of these hundred-year-old and older trees over the past 21 years, and we are the biggest conservationist in the region. I think we humans need to become more humble and realize that we couldn't exist without these trees, not to mention the treasures they give us each year through their harvest. We're probably the first company ever to work with trees, from Tree to Beauty, to reach a valuation of over a billion dollars. However, it was never my goal, and to be honest, it should be much more, given the innovations we've achieved over the past 21 years and the global innovations and new brands that from Tree to Beauty will be launching in 2025.' About Oliveda International, Inc. Oliveda International, Inc. and its subsidiary, Olive Tree People Inc., as well as the European companies, Olive Tree People Europe AG and Oliveda Deutschland GmbH, as well as Olive Tree Farmers SL, were founded by the German real estate investor Thomas Lommel and have more than 20 years of experience in management and organic certification growing mountain olive trees, in the extraction of first-class, internationally award-winning extra virgin olive oils, the extraction of hydroxytyrosol, and in the production and distribution of cosmetic and holistic waterless products related to the olive tree. Lommel is the inventor of the Olive Tree Therapy 10 years in 14 days as well as the inventor of olive matcha, which is based on the ground olive leaf. Also unique is the coffee replacement developed by Lommel, which is based on olive leaf and hydroxytyrosol. In addition, Lommel is successfully active in the rapidly growing mindfulness industry with the olive tree sound bath meditation he developed and the frequencies of his olive trees, which he makes available worldwide. In addition to the registered beauty brands, Oliveda and LA Dope, as well as Re:connected to Nature, The Intuition of Nature, and Olive Mush, to name just a few brands, Lommel is the region's largest conservationist and protector of over 30,000 one-hundred-year-old mountain olive trees, and, with his Thomas Lommel Foundation, he brings the water that he does not use into his waterless beauty products to the people of Africa by building water wells on site. In addition to online sales and a Europe-wide branch network of thousands of retail stores, Oliveda Deutschland GmbH operates its own flagship stores in Berlin and Düsseldorf. The brand's treatment concepts are unique worldwide, and their effectiveness has been confirmed by conventional medicine. Read our book The Olive Tree Therapy 10 Years in 14 Days . Waterless beauty has been called 'The Next Big Thing' in articles in U.S. Vogue , Harper's Bazaar , InStyle , Elle , Madame , Forbes , and many other industry publications, as well as by Mintel, a world-leading futurology institute. Gigi Hadid and many other celebrities are already Oliveda fans and support its success. Further information on Oliveda International, Inc. and its subsidiaries and associate companies and brands can be found at Forward-Looking Statements This press release may contain statements, estimates or projections that constitute 'forward-looking statements' pursuant to the safe harbor provisions of the U.S. federal securities laws. Generally, the words 'believe,' 'expect,' 'intend,' 'estimate,' 'anticipate,' 'project,' 'will' and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties, which may be found in the Company's filings with OTC Markets Group Inc., that could cause actual results to differ materially from the Company's historical experience and present expectations or projections. Investors should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation or intention to publicly update or revise any forward-looking statements unless otherwise required by law. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
3 hours ago
- Business Wire
Resecurity Appoints Luiz Cota as Territory Manager for Brazil
LOS ANGELES--(BUSINESS WIRE)-- Resecurity, Inc., a global leader in cybersecurity and threat intelligence solutions, is pleased to announce the appointment of Luiz Cota as Territory Manager for Brazil. With more than three decades of experience in technology and cybersecurity across Latin America, Cota will spearhead Resecurity's efforts to expand its footprint in Brazil and strengthen cyber defense capabilities for local enterprises, public institutions, and critical infrastructure. Throughout his career, Luiz Cota has held senior roles at leading cybersecurity and technology firms including Cisco, IronPort, SurfControl, Fidelis, and Offensive Security. His extensive background in both commercial and technical domains positions him to effectively adapt and deliver Resecurity's advanced threat intelligence solutions to meet the unique needs of the Brazilian market. Cota brings a rare combination of deep technical expertise and strategic business insight. He founded Brazil's first cyber-insurance brokerage, advising startups and established enterprises on cyber risk mitigation, threat modeling, and digital resilience. With a clear understanding of Brazil's regulatory framework, digital economy, and emerging threat landscape, he is uniquely equipped to help organizations implement localized, intelligence-driven cybersecurity strategies. 'Luiz offers a profound understanding of the Brazilian cybersecurity landscape and a proven ability to execute complex go-to-market strategies,' said Gene Yoo, CEO of Resecurity. 'His leadership will be key as we accelerate our growth in Latin America and support Brazilian organizations in building stronger defenses against rapidly evolving cyber threats.' Luiz Cota holds a degree in Electronic Engineering, a specialization in marketing, and an MBA, enabling him to bridge the gap between technical innovation and business execution. He will lead Resecurity's regional initiatives in partnership development, threat intelligence delivery, and customer success, with a focus on empowering local partners and clients to anticipate, detect, and respond to cyber risks with greater precision. 'Cybersecurity has become a strategic priority in Brazil as digital transformation advances across all sectors,' said Luiz Cota. 'I'm excited to join Resecurity and bring world-class cyber intelligence capabilities to organizations committed to protecting their data, infrastructure, and people.' This appointment marks a significant step in Resecurity's regional expansion strategy, reinforcing its commitment to providing scalable, proactive, and locally relevant cybersecurity solutions throughout Latin America. About Resecurity Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit
Business Wire
3 hours ago
- Business Wire
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. ('Tempus') (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 (the 'Notes') in a private placement (the 'Offering') to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'). The aggregate principal amount of the Offering was increased from the previously announced offering size of $400 million. Tempus also granted the initial purchasers of the Notes an over-allotment option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $100 million aggregate principal amount of Notes. The sale of the Notes to the initial purchasers is expected to close on July 3, 2025, subject to customary closing conditions. The Notes will be general unsecured obligations of Tempus and will accrue interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on January 15, 2026, at a rate of 0.75% per year. The Notes will mature on July 15, 2030, unless earlier converted, redeemed or repurchased. Tempus estimates that the net proceeds from the Offering will be approximately $625.3 million (or approximately $721.7 million if the initial purchasers exercise their over-allotment option to purchase additional Notes in full), after deducting the initial purchasers' discounts and commissions and estimated Offering expenses payable by Tempus. Tempus expects to use the net proceeds from the Offering to repay $274.7 million principal amount of its outstanding senior secured term loans, plus accrued and unpaid premium and interest, to pay the approximately $36.2 million cost of the capped call transactions described below, and for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses or technologies, working capital, operating expenses, capital expenditures and repayment of additional indebtedness. If the initial purchasers exercise their over-allotment option to purchase additional Notes, Tempus expects to use a portion of the net proceeds from the sale of the additional Notes to enter into additional capped call transactions and for the general corporate purposes described above. Prior to April 15, 2030, the Notes will be convertible at the option of the noteholders only if one or more specific conditions are met. On or after April 15, 2030 until the close of business on the second scheduled trading day immediately preceding the maturity date, the Notes will be convertible in integral multiples of $1,000 principal amount at the option of the noteholders at any time regardless of these conditions. Upon conversion, Tempus will pay or deliver, as the case may be, cash, shares of Tempus' Class A common stock, par value $0.0001 per share ('Class A common stock') or a combination of cash and shares of Class A Common stock, at its election. The initial conversion rate is 11.8778 shares of Class A Common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $84.19 per share of Class A Common stock, which represents a conversion premium of approximately 32.5% to the last reported sale price of Class A Common stock on the Nasdaq Global Select Market on June 30, 2025), and will be subject to customary anti-dilution adjustments. Tempus may not redeem the Notes prior to July 20, 2028. Tempus may redeem for cash all or any portion of the Notes (subject to the partial redemption limitation described below), at its option, on or after July 20, 2028 and prior to the 21 st scheduled trading day immediately preceding the maturity date of the Notes if the last reported sale price of Class A common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Tempus provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. If Tempus redeems fewer than all of the outstanding Notes, at least $100 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of, and after giving effect to, delivery of the relevant notice of redemption. If Tempus undergoes a 'fundamental change' (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, holders of the Notes may require Tempus to repurchase for cash all or any portion of their Notes in principal amounts of $1,000 or an integral multiple thereof at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if Tempus delivers a notice of redemption, Tempus will, in certain circumstances, increase the conversion rate of the Notes for a holder who elects to convert its Notes in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period, as the case may be. In connection with the pricing of the Notes, Tempus entered into privately negotiated capped call transactions with one of the initial purchasers and certain other financial institutions (the 'Option Counterparties'). The capped call transactions cover, subject to customary adjustments, the number of shares of Class A common stock initially underlying the Notes. The capped call transactions are expected generally to reduce the potential dilution to the Class A common stock upon any conversion of Notes and/or offset any cash payments Tempus is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions relating to the Notes will initially be $111.1950, which represents a premium of 75% over the last reported sale price of the Class A common stock on the Nasdaq Global Select Market on June 30, 2025, and is subject to certain adjustments under the terms of the capped call transactions. In connection with establishing their initial hedges of the capped call transactions, Tempus expects the Option Counterparties or their respective affiliates will enter into various derivative transactions with respect to the Class A common stock and/or purchase shares of Class A common stock concurrently with or shortly after the pricing of the Notes, including with, or from, as the case may be, certain investors in the Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Class A common stock or the Notes at that time. In addition, the Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Class A common stock and/or purchasing or selling Class A common stock or other securities of Tempus in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so during the 20 trading day period beginning on the 21 st scheduled trading day prior to the maturity date of the Notes, or, to the extent Tempus exercises the relevant election under the capped call transactions, following any repurchase, redemption or conversion of the Notes). This activity could also cause or avoid an increase or a decrease in the market price of the Class A common stock or the Notes which could affect a noteholder's ability to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of Notes, it could affect the number of shares, if any, and value of the consideration that a noteholder will receive upon conversion of its Notes. The Notes and any shares of Class A common stock issuable upon conversion of the Notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the proposed Offering, including statements concerning the proposed and the anticipated completion, timing and size of the proposed Offering of the Notes, the capped call transactions, the anticipated use of proceeds from the Offering, and the potential impact of the foregoing or related transactions on dilution to holders of the Class A common stock and the market price of the Class A common stock or the Notes or the conversion price of the Notes. These forward-looking statements are based on Tempus' current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Tempus' actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. These risks include, but are not limited to market risks, trends and conditions. These and other risks are more fully described in Tempus' filings with the Securities and Exchange Commission ('SEC'), including in the section entitled 'Risk Factors' in its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 24, 2025, as well as other filings Tempus may make with the SEC in the future. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
